Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. TriSalus Life Sciences's pretax income for the
three
months ended in Jun. 2026 was $-9.18 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-28.20 Mil.
TriSalus Life Sciences's pretax margin was -80.50%.
During the past 5 years, TriSalus Life Sciences's highest Pretax Margin was -60.84%. The lowest was -380.53%. And the median was -320.64%.
During the past 5 years, TriSalus Life Sciences's highest Pretax Margin was -60.84%. The lowest was -380.53%. And the median was -320.64%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Pre-Tax Income Related Terms
TriSalus Life Sciences Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSI vs TMCI, SENS, SGHT: Pre-Tax Income Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Pre-Tax Income vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Pre-Tax Income of $-28.20 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on TriSalus Life Sciences and its competitors.
Is TriSalus Life Sciences' Pre-Tax Income too high?
TriSalus Life Sciences' current Pre-Tax Income is $-28.20 Mil. Overall, TriSalus Life Sciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Pre-Tax Income compare to TMCI and SENS?
TriSalus Life Sciences' Pre-Tax Income of $-28.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Medical Devices & Instruments company?
A good Pre-Tax Income depends on the Medical Devices & Instruments industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on TriSalus Life Sciences and its competitors. TriSalus Life Sciences's current Pre-Tax Income is $-28.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.76, compared to a current price of $5.60 — trading 48.9% above its estimated fair value. The current Pre-Tax Income is $-28.20 Mil. TriSalus Life Sciences' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Pre-Tax Income is $-28.20 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $5.60 is trading 48.9% above its estimated GF Value™ of $3.76.
GuruFocus considers TriSalus Life Sciences to be Significantly Overvalued.
Key valuation signals for TLSI:
Pre-Tax Income: $-28.20 Mil
GF Value™: $3.76 vs. price of $5.60 (48.9% above fair value)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
24GF Score
Get the complete analysis for TLSI
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
